An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
The purpose of this study is to understand if scheduled glucarpidase reduces the levels of methotrexate in patients’ blood and lead to shorter hospitalizations and a reduction in toxicities.
25 years or older with osteosarcoma
Recommended treatment includes methotrexate
25 - 100
Healthy Volunteers Needed
Duration of Participation
10 weeks of treatment, then 30 days of follow-up time.
Knight Clinical Trials Office